Abstract
Purpose
To investigate the effects of MK906, a selective 5 alpha reductase (5αR) type 2 (5αR2) inhibitor, and of MK386, a specific 5αR1 inhibitor, on the cellular proliferation of androgen-dependent human prostatic cancer (PCa) cells in cultures of cells derived from bioptic and surgical tissues.
Methods
In this study we tested the effects of MK906 and MK386 in 30 cultures derived from PCa, 6 from PIN and 10 from benign prostatic hyperplasia specimens.
Results
Prostate primary cultures under short-term conditions (with <4 subcultures) represent a mixture of epithelial and stromal cells. Epithelial cells require testosterone (T) for optimal growth, but were not able to grow in the presence of T under long-term conditions even if DHT was able to induce cellular proliferation to a similar extent in both conditions, suggesting that 5αR can be lost in long-term cultures. Therefore, our studies were performed under short-term conditions. Both 5αR inhibitors decreased cell proliferation significantly and dose-dependently in all the samples tested. MK906 was more efficient than MK386 in 7 out of 10 cultures derived from BPH tissues, in 4 out of 6 cultures derived from PIN and in 18 out of 30 cultures derived from PCa. In 3 out of 10 BPH, in 2 out of 6 PIN and in 5 out of 30 PCa-derived cultures, both inhibitors presented similar efficacy, whereas in 1 out of 10 BPH and 7 out of 30 PCa-derived cultures MK386 was more efficient than MK906. In addition, MK386 was more efficient than MK906 in 4 out of 15 non-metastatic PCa and 2 out of 7 metastatic PCa-derived cultures.
Conclusions
Considering that 5αR1 (responsible primarily for androgenic catabolism) is mostly expressed in epithelial cells and that 5αR2 (responsible for local DHT synthesis and release) is expressed in the stromal cells (which provides several paracrine growth factors and DHT itself to the epithelial cells), our experiments suggest that the inhibition of both 5αR1 and 5αR2 by MK386 and MK906, respectively, may have therapeutic potential in order to reduce the growth and progression of human prostatic cancers, through the inhibition of autocrine or paracrine mechanisms involving the stromal cell compartment. In addition, some effects of 5αR inhibitors could be mediated by estrogens, which are synthesized by the aromatase enzyme present in the epithelial cells. These aspects could be considered in order to improve the therapeutical management of PCa and for future clinical trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akalu A, Dlmajian DA, Highshaw RA, Nichols PW, Reichardt JK (1999) Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5alpha-reductase during prostate cancer progression. J Urol 161:1355–1358
Asadi FK, Sharifi R (1995) Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines. Int Urol Nephrol 27:67–80
Aumuller G, Eicheler W, Renneberg H, Adermann K, Vilja P, Forssmann WG (1996) Immunocytochemical evidence for differential subcellular localization of 5 alpha-reductase isoenzymes in human tissues. Acta Anat (Basel) 156:241–252
Berman DM, Russell DW (1993) Cell-type-specific expression of rat steroid 5 alpha-reductase isozymes. Proc Natl Acad Sci U S A 90:9359–9363
Bologna M, Vicentini C, Festuccia C, Muzi P, Napolitano T, Biordi L, Miano L (1988) Short-term tissue culture of prostatic carcinoma samples provides useful biological parameters related to patient prognosis. Eur Urol 15:243–247
Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C (1995) Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology 45:282–290
Bonkhoff H, Stein U, Remberger K (1994) The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24:114–118
Bonkhoff H, Stein U, Aumuller G, Remberger K (1996) Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas. Prostate 29:261–267
Brawley OW (2003) Hormonal prevention of prostate cancer. Urol Oncol 21:67–72
Bruchovsky N, Wilson JD (1968) The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012–2021
Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL (2002) Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res 8:1003–1007
Degeorges A, Tatoud R, Fauvel-Lafeve F, Podgorniak MP, Millot G, Cremoux P de, Calvo F (1996) Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int J Cancer 68:207–214
Dulbecco R, Bologna M, Unger M (1979) Differentiation of a rat mammary cell line in vitro. Proc Natl Acad Sci U S A 76:1256–1260
El-Alfy M, Pelletier G, Hermo LS, Labrie F (2000) Unique features of the basal cells of human prostate epithelium. Microsc Res Tech 51:436–446
Festuccia C, Angelucci A, Gravina GL, Muzi P, Miano R, Vicentini C, Bologna M (2005) Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. Int J Oncol (in press)
Fixemer T, Remberger K, Bonkhoff H (2003) Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54:79–87
Habib FK, Ross M, Bayne CW (1999) Factors controlling the expression of 5alpha-reductase in human prostate: a possible new approach for the treatment of prostate cancer. Eur Urol 35:439–442
Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P (1995) Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 31:14–24
Hayward SW, Rosen MA, Cunha GR (1997) Stromal-epithelial interactions in the normal and neoplastic prostate. Br J Urol 79 [Suppl 2]:18–26
Huang ZQ, Li J, Wong J (2002) AR possesses an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 16:924–937
Lam JS, Romas NA, Lowe FC (2003) Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology 61:354–358
Leav I, Schelling KH, Adams JY, Merk FB, Alroy J (2001) Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 47:149–163
Lieberman R (2003) Evolving strategies for prostate cancer chemoprevention trials. World J Urol 21:3–8
Linja MJ, Savinainen KJ, Tammela TL, Isola JJ, Visakorpi T (2003) Expression of ERalpha and ERbeta in prostate cancer. Prostate 55:180–186
Liu AY, True LD, LaTray L et al. (1997) Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci. U S A 94:10705–10710
Maggiolini M, Bonofiglio D, Pezzi V et al. (2002) Aromatase overexpression enhances the stimulatory effects of adrenal androgens on MCF7 breast cancer cells. Mol Cell Endocrinol 193:13–18
Merchant DJ, Clarke SM, Ives K, Harris S (1983) Primary explant culture: an in vitro model of the human prostate. Prostate 4:523–542
Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092–3096
Moss ML, Kuzmic P, Stuart JD et al. (1996) Inhibition of human steroid 5alpha reductases type I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism. Biochemistry 35:3457–3464
Negri-Cesi P, Poletti A, Colciago A, Magni P, Martini P, Motta M (1998) Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate 34:283–291
Negri-Cesi P, Colciago A, Poletti A, Motta M (1999) 5Alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3. Prostate 41:224–232
Niu Y, Xu Y, Zhang J, Bai J, Yang H, Ma T (2001) Proliferation and differentiation of prostatic stromal cells. BJU Int 87:386–393
Pasquali D, Rossi V, Esposito D, Abbondanza C, Puca GA, Bellastella A, Sinisi AA (2001) Loss of estrogen receptor beta expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J Clin Endocrinol Metab 86:2051–2055
Rajan R, Vanderslice R, Kapur S, Lynch J, Thompson R, Djakiew D (1996) Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28:1–9
Sadar MD, Gleave ME (2000) Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res 60:5825–5831
Sherwood JB, McConnell JD, Vazquez DJ, Lin VK, Roehrborn CG (2003) Heterogeneity of 5 alpha-reductase gene expression in benign prostatic hyperplasia. J Urol 169:575–579
Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW (2002) Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 95:1864–1868
Torlakovic E, Lilleby W, Torlakovic G, Fossa SD, Chibbar R (2002) Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. Hum Pathol 33:646–651
Torring N, Sorensen BS, Bosch ST, Klocker H, Nexo E (1998) Amphiregulin is expressed in primary cultures of prostate myofibroblasts, fibroblasts, epithelial cells, and in prostate tissue. Prostate Cancer Prostatic Dis 1:262–267
Ueda T, Mawji NR, Bruchovsky N, Sadar MD (2002) Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem 277:38087–38094
Vicentini C, Gravina GL, Angelucci A et al. (2004) Detection of telomerase activity in prostate massage samples improves differentiating prostate cancer from benign prostatic hyperplasia. J Cancer Res Clin Oncol 130:217–221
Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS (1999) Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase. Endocrinology 140:4509–4515
Ye Q, Cinar B, Edlund M, Chung LW, Zhau HE (2001) Inhibition of growth and cell cycle arrest of ARCaP human prostate cancer cells by ectopic expression of ER-alpha. Mol Cell Biochem 228:105–110
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Festuccia, C., Angelucci, A., Gravina, G.L. et al. Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. J Cancer Res Clin Oncol 131, 243–254 (2005). https://doi.org/10.1007/s00432-004-0632-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-004-0632-1